Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

End of study PETAL Study NCT00554164 - End of study

- 23.11.16 - 1 Formular, 4 Itemgruppen, 25 Datenelemente, 2 Sprachen

Itemgruppen: Comorbidity, Discontinuation, Adverse event, Footer module

Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

SAE Form RICH study NCT02669589

- 20.09.21 - 1 Formular, 9 Itemgruppen, 51 Datenelemente, 1 Sprache

Itemgruppen: Patient Information, Seriousness criteria, Serious Adverse Event (SAE), Treatment of SAE, Drugs, Relevant Medical History, Tests and procedures, Comments, Investigator

NCT02669589 EudraCT-Nr. 2014-004854-33 REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS WITH ACUTE KIDNEY INJURY Study Chair: Alexander Zarbock, MD University Hospital Muenster

Adverse events LenaMain-Study - Adverse Events CTC

- 17.03.16 - 1 Formular, 1 Itemgruppe, 24 Datenelemente, 1 Sprache

Itemgruppe: Adverse Events

A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

On-Study - Adverse Events - 2804058v1.0 - Adverse Events

- 09.01.15 - 1 Formular, 3 Itemgruppen, 22 Datenelemente, 1 Sprache

Itemgruppen: DCP Template Header, Adverse Events, DCP Template Footer

The Division of Cancer Prevention's adverse events case report form (CRF) template. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5C3563B2-CBFA-3E8F-E044-0003BA3F9857

Ewing Study SAE DRKS00003588 - SAE

- 04.08.14 - 1 Formular, 2 Itemgruppen, 4 Datenelemente, 2 Sprachen

Itemgruppen: Show identification of patient, SAE

EWING 2008, EudraCT 2008-003658-13, http://clinicaltrials.gov/ct2/show/NCT00824083

Adverse Event: Heparin RICH study NCT02669589

- 08.07.16 - 1 Formular, 6 Itemgruppen, 21 Datenelemente, 1 Sprache

Itemgruppen: Patient Information, Adverse Event Description, Duration, Therapy, Comments, Case report form data

NCT02669589 EudraCT-Nr. 2014-004854-33 REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS WITH ACUTE KIDNEY INJURY Study Chair: Alexander Zarbock, MD University Hospital Muenster

Adverse Event: Citrate RICH study NCT02669589 - Adverse Event: Citrat RICH study NCT02669589

- 08.07.16 - 1 Formular, 6 Itemgruppen, 21 Datenelemente, 1 Sprache

Itemgruppen: Patient Information, Adverse Event Description, Duration, Therapy, Comments, Case report form data

NCT02669589 EudraCT-Nr. 2014-004854-33 REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS WITH ACUTE KIDNEY INJURY Study Chair: Alexander Zarbock, MD University Hospital Muenster

Rotavirus Vaccine RIX4414 Study NCT00289172 - Serious Adverse Event

- 13.04.18 - 1 Formular, 14 Itemgruppen, 51 Datenelemente, 1 Sprache

Itemgruppen: Header, Serious adverse event, Seriousness, Demography data, SECTION 4, SECTION 5, Relevant Medical Conditions, Other relevant risk factors, Document section Concomitant Medications, Details of investigational product, Details of relevant Assessments, Narrative Remarks, Investigator's signature, follow-up information SAE

A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Study ID:103792 Clinical Study ID:103792 Study Title: A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Patient Level Data:Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:NCT00289172 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: BIO ROTA; Rotarix Study Indication: Infections, Rotavirus CRF Seiten: 375-430

Rotavirus Vaccine RIX4414 Study NCT00289172 - gastroenteritis, concomitant vaccination, medication and non-serious adverse events

- 13.04.18 - 1 Formular, 8 Itemgruppen, 38 Datenelemente, 2 Sprachen

Itemgruppen: Header, Gastroenteritis Episodes, Gastroenteritis protocol, Concomitant Vaccination, Concomitant Vaccination, Medication, Medication, Non-serious Adverse Events

A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Study ID:103792 Clinical Study ID:103792 Study Title: A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Patient Level Data:Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:NCT00289172 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: BIO ROTA; Rotarix Study Indication: Infections, Rotavirus CRF Seiten: 375-430